How At-Home Diagnostic Kits Are Transforming Healthcare in the U.S.

A major concern that the healthcare industry has been dealing with for a long time is delivering accurate, reliable, and clinically meaningful diagnostic testing closer to patients. While telemedicine has made it easier for patients to consult healthcare professionals and digital health platforms have improved communication, diagnostic testing has traditionally remained centred on laboratories, hospitals, and physicians' offices. That model is gradually changing. Consumers are increasingly willing to perform portions of diagnostic testing themselves, supporting a more accessible, patient-centred approach to healthcare that emphasizes convenience, timely information, and informed decision-making.

The U.S. has become one of the leading markets driving this transition. At-home diagnostic kits are no longer viewed solely as emergency or pandemic-related tools. Instead, they are becoming an established component of preventive care and disease management. Whether for infectious diseases, fertility, chronic disease monitoring, or certain genetic tests, Americans are increasingly using these kits to take a more active role in managing their health.

Tasks that previously required physician appointments, laboratory visits, travel, and insurance-related processes can now, for many approved tests, be initiated or completed from home. This shift is prompting healthcare providers, clinical laboratories, insurers, pharmaceutical companies, and public health organizations to adapt their care delivery models to accommodate home-based testing.

Recent product launches also reflect this trend. Noom introduced its at-home Biomarkers Test Kit for eligible members in the United States, enabling users to monitor biomarkers such as HbA1c, ApoB, triglycerides, and high-sensitivity C-reactive protein (hs-CRP). Using the Tasso+ blood collection device, users can collect a blood sample at home and send it to a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory for analysis, with results delivered through the Noom app.

The Consumerization of Diagnostics

The development of home-based diagnostic products reflects the broader consumerization of healthcare in the United States. Patients increasingly expect healthcare experiences that match the convenience and accessibility offered by digital banking, e-commerce, and other consumer services. Waiting several days for a physician appointment or travelling to an external laboratory for routine diagnostic testing is becoming less attractive for many consumers when clinically appropriate home-testing options are available.

American consumers already rely on smartphones for many aspects of daily life, including appointment scheduling, prescription management, telehealth consultations, and health monitoring. As a result, they increasingly expect diagnostic services to offer the same level of convenience and speed. Home-based testing products meet this expectation by allowing eligible individuals to collect samples without many of the logistical challenges associated with clinic-based testing.

Younger adults continue to embrace home diagnostics as part of a proactive approach to health management. However, adoption is also increasing among older adults and individuals living with chronic conditions, who use home-testing options to reduce unnecessary clinic visits while sharing clinically relevant information with healthcare providers. As a result, diagnostics are becoming more decentralized, with patients taking a more active role in initiating certain types of testing while remaining connected to healthcare professionals when required.

According to U.S. Census Bureau population estimates, adults of working age continue to account for the largest share of the U.S. population, while the proportion of adults aged 65 years and older continues to increase because of demographic ageing. This ageing population is expected to support demand for home-based diagnostic solutions, particularly for chronic disease monitoring, preventive screening, and routine health assessment.

COVID-19 Changed More Than Testing Habits

The COVID-19 pandemic accelerated awareness of at-home diagnostics, but its long-term impact extends well beyond infectious disease testing. Millions of Americans became familiar with self-administered testing procedures, sample collection, result interpretation, and digital reporting through connected health platforms.

This widespread behavioural shift reduced many of the concerns associated with self-testing. Before the pandemic, many consumers questioned whether diagnostic procedures could be performed accurately outside clinical settings. The widespread use of FDA-authorized COVID-19 rapid antigen tests increased familiarity with home testing and helped improve public confidence in properly validated at-home diagnostic products.

The pandemic also influenced the regulatory environment. Regulatory agencies gained valuable experience reviewing and authorizing home-use diagnostic devices, contributing to more established pathways for evaluating future at-home diagnostic technologies while maintaining safety and performance standards.

Rather than serving as a temporary response to a public health emergency, the pandemic accelerated consumer acceptance of home-based diagnostics and encouraged healthcare companies to expand investment in remote testing technologies, digital health integration, and connected care solutions.

Chronic Disease Management Is the Next Growth Frontier

While infectious disease testing generated early momentum, chronic disease management is emerging as one of the most significant long-term opportunities for at-home diagnostics in the United States.

Chronic conditions account for a substantial proportion of U.S. healthcare expenditure. Diseases such as diabetes, cardiovascular disease, chronic kidney disease, and metabolic disorders require continuous monitoring rather than occasional diagnostic assessments, making them well suited to home-based testing solutions.

Consumers increasingly seek timely health information between routine physician visits. Instead of waiting months for annual check-ups, many individuals can monitor selected biomarkers at home and share the results with healthcare professionals when appropriate. Healthcare providers may also benefit from more continuous patient-generated health data, supporting earlier identification of potential health changes and more informed clinical decision-making.

The economic case is equally compelling. Preventive monitoring and earlier detection may help reduce avoidable hospital admissions and improve long-term disease management, particularly as healthcare systems continue to address rising costs associated with chronic illnesses. Consequently, many healthcare organizations and diagnostic companies increasingly view at-home testing as one component of broader disease management and preventive care strategies rather than a standalone testing solution.

Recent regulatory developments have also expanded the range of conditions that can be screened at home. Teal Health® received U.S. Food and Drug Administration (FDA) approval for the Teal Wand™, an at-home self-collection device that enables eligible individuals to collect a vaginal sample for cervical cancer screening under an approved clinical workflow. The approval represents an important milestone in expanding access to preventive screening through home-based diagnostics.

The Heart Failure Epidemiology and Outcomes Statistics 2025 Update estimates that approximately 6.7 million U.S. adults aged 20 years and older are living with heart failure, with prevalence projected to increase to nearly 8.7 million by 2030. This growing disease burden is expected to strengthen demand for home-based monitoring technologies that support ongoing patient management alongside clinical care.

Digital Integration Is Becoming the Real Differentiator

While many consumers focus primarily on the physical test kits, one of the most significant developments is the integration of diagnostics with digital health platforms. Increasingly, at-home diagnostic products are combined with mobile applications, cloud-based analytics, telehealth services, and electronic health record (EHR) connectivity, making the test part of a broader healthcare ecosystem rather than a standalone product.

Consumers increasingly expect rapid result interpretation, personalized health insights, and clear guidance on appropriate next steps after receiving their test results. Digital platforms can help users understand their results, facilitate virtual consultations with healthcare professionals, maintain longitudinal health records, and support ongoing disease monitoring.

Artificial intelligence (AI) and predictive analytics are also being incorporated into selected digital health platforms to improve data interpretation and personalize health recommendations. While clinical decisions continue to require healthcare professional oversight, AI-enabled tools can assist by identifying trends, monitoring biomarker changes over time, and supporting more proactive disease management.

As digital health technologies continue to mature, the competitive advantage of at-home diagnostics is likely to depend not only on test accuracy but also on how effectively diagnostic data are integrated into broader clinical care pathways.

Expanding Access Across Underserved Communities

At-home diagnostics offer an important opportunity to improve healthcare access, particularly for underserved and geographically remote populations. Many communities across the United States continue to face barriers to healthcare, including limited access to clinical laboratories, shortages of healthcare professionals, transportation challenges, and longer waiting times for appointments.

Home diagnostic kits can help reduce some of these barriers by allowing eligible individuals to collect samples from home and access testing without unnecessary travel. Although these products are not intended to replace comprehensive medical care, they can complement traditional healthcare services by improving access to screening and facilitating earlier clinical evaluation when necessary.

Public health agencies, healthcare systems, and community health organizations are increasingly evaluating the role of home-based diagnostics in expanding screening programmes for conditions that are frequently underdiagnosed or detected at later stages. Improved access to screening may contribute to earlier diagnosis, more timely intervention, and better long-term health outcomes.

Beyond improving patient convenience, expanding access to home-based diagnostics may also help reduce healthcare costs by supporting preventive care and enabling earlier disease detection, particularly for chronic conditions that require ongoing monitoring.

Regulatory Confidence Is Strengthening Market Expansion

The regulatory environment for at-home diagnostics has become more structured as the U.S. Food and Drug Administration (FDA) has expanded its experience evaluating home-use diagnostic devices across multiple disease areas. Manufacturers now have clearer expectations regarding clinical validation, analytical performance, usability studies, labelling requirements, cybersecurity considerations for connected devices, and post-market surveillance.

Regulatory confidence remains essential because consumer trust depends on the reliability, safety, and clinical performance of home-based diagnostic products. Widespread adoption is more likely when consumers and healthcare professionals have confidence that these products meet established regulatory standards.

The U.S. regulatory framework continues to evolve alongside advances in molecular diagnostics, digital health technologies, artificial intelligence, and remote patient monitoring. Regulators face the ongoing challenge of encouraging innovation while ensuring patient safety, data privacy, and product effectiveness.

Industry stakeholders generally view this regulatory evolution as a positive development because greater regulatory clarity reduces uncertainty, supports investment in research and development, and facilitates the commercialization of clinically validated at-home diagnostic solutions.

Key U.S. Companies Driving Innovation

Everlywell

Everlywell, headquartered in Austin, Texas, was among the early companies to popularize direct-to-consumer (DTC) laboratory testing by offering a broad portfolio of at-home health and wellness test kits. Its objective is to improve access to laboratory testing while enabling consumers to obtain physician-reviewed results without always requiring an in-person clinic visit.

Everlywell has expanded beyond individual diagnostic products by integrating telehealth services, physician consultations, and digital result reporting into its platform. This reflects the broader shift toward connected, consumer-focused healthcare, where diagnostics, virtual care, and follow-up services are delivered through a single digital ecosystem.

As consumer interest in preventive healthcare continues to grow, Everlywell has strengthened its position by offering tests that help individuals monitor biomarkers and health indicators over time. This approach supports consumers seeking continuous health monitoring rather than relying solely on episodic medical appointments.

LetsGetChecked

LetsGetChecked has established a significant presence in the U.S. at-home diagnostics market by offering home sample collection and CLIA-certified laboratory testing across multiple health categories. The company focuses on providing clinically validated testing services that remain connected to licensed healthcare professionals throughout the testing process.

A distinguishing feature of its business model is its emphasis on integrated care pathways. Beyond delivering laboratory results, LetsGetChecked offers access to physician consultations, prescription services where clinically appropriate, and ongoing health management support.

This approach addresses one of the key limitations of direct-to-consumer diagnostics: laboratory results alone may not improve patient outcomes without appropriate medical interpretation and follow-up care. By integrating diagnostic testing with clinical support, the company aims to bridge the gap between testing, diagnosis, and treatment.

Cue Health

Based in San Diego, California, Cue Health gained national recognition through its molecular diagnostic platform designed to deliver laboratory-quality testing in decentralized settings, including homes and workplaces.

Rather than focusing exclusively on individual diagnostic tests, Cue Health developed a connected platform combining portable molecular testing devices, digital software, and telehealth capabilities. This integrated approach illustrates the industry's broader move toward combining diagnostics with digital healthcare services rather than offering standalone testing products.

While the company has undergone strategic restructuring following the decline in COVID-19 testing demand, its molecular diagnostics platform continues to demonstrate how connected diagnostic technologies can support decentralized healthcare delivery and remote patient management.

ixlayer

Based in San Francisco, California, ixlayer occupies a different segment of the at-home diagnostics ecosystem. Rather than manufacturing diagnostic kits, the company provides digital infrastructure that enables healthcare organizations, laboratories, life sciences companies, and health plans to launch and manage large-scale diagnostic programmes.

Its platform supports patient enrolment, logistics management, sample collection workflows, laboratory integration, digital engagement, and secure delivery of test results. This infrastructure highlights the growing importance of software platforms in scaling population health and home-testing initiatives.

One notable example is ixlayer's collaboration with L.A. Care Health Plan, which expanded access to at-home screening for colorectal cancer, diabetes, and kidney disease among underserved communities. The programme combined home diagnostic kits with multilingual outreach and personalized engagement strategies to improve participation in preventive health screening.

Major U.S. At-Home Diagnostic Products and Developments

The Emerging Competitive Landscape

Competition in the U.S. at-home diagnostics market is expanding beyond traditional diagnostic manufacturers. Established laboratory companies, digital health providers, healthcare technology firms, and consumer-focused startups are introducing new testing solutions that combine diagnostics with telehealth, remote patient monitoring, and digital health platforms.

Retail pharmacy chains, healthcare providers, insurers, and diagnostic companies are also forming strategic partnerships to integrate home-based testing into broader care delivery models. As a result, the traditional boundaries between diagnostics, telehealth, pharmacy services, and digital health are becoming increasingly interconnected.

This convergence is creating new opportunities for companies capable of delivering integrated healthcare experiences while increasing competition across the sector. Competitive differentiation is shifting from the availability of individual diagnostic tests to factors such as clinical validation, digital integration, patient engagement, interoperability with healthcare systems, and the ability to support end-to-end care pathways.

Looking ahead, sustained market growth is likely to depend on continued regulatory confidence, reimbursement support, consumer trust, and the ability of companies to integrate diagnostic data into routine clinical workflows.

Looking Ahead

At-home diagnostic kits are becoming an increasingly important component of healthcare delivery in the United States. Beyond improving convenience, they support a broader transition toward more decentralized, digitally connected, and patient-centred healthcare.

Advances in remote diagnostics, artificial intelligence, digital health platforms, connected medical devices, and personalized medicine are expected to create new opportunities in preventive healthcare, chronic disease management, and population health programmes. As test accuracy, usability, and digital integration continue to improve, the distinction between home-based and clinic-based diagnostics is expected to narrow for many appropriate testing applications.

Challenges remain, including reimbursement policies, regulatory compliance, data privacy, equitable access to healthcare, and the need for continued clinical validation of emerging diagnostic technologies. Nevertheless, the long-term direction of the market is becoming increasingly clear. Consumers are taking a more active role in monitoring their health, while healthcare providers are incorporating home-based diagnostics into broader models of preventive and continuous care.

As healthcare delivery continues to evolve, at-home diagnostics are expected to complement traditional laboratory services rather than replace them, improving access to timely testing while strengthening collaboration between patients, clinicians, and digital healthcare platforms.